Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. by Ilett, E et al.
1 
 
Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint 1 
Blockade Improves Anti-tumor Therapy 2 
 3 
Elizabeth Ilett 1,2*,
  Timothy Kottke1*, Jill Thompson1, Karishma Rajani1, Shane Zaidi1,3, Laura 4 
Evgin1, Matt Coffey4, Christy Ralph2, Rosa Diaz5, Hardev Pandha6, Kevin Harrington3, Peter 5 
Selby2, Richard Bram7, Alan Melcher2**, Richard Vile1,2,7,** 6 
 7 
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905; 2Leeds Institute of 8 
Cancer and Pathology, St. James’ University Hospital, Leeds, UK; 3The Institute of Cancer 9 
Research, 237 Fulham Road, London, SW3; 4Oncolytics Biotech Incorporated, Calgary, 10 
Canada; 5Vyriad, 221 1st Avenue SW, Suite 102, Rochester, MN; 6University of Surrey, 11 
Guildford, UK; 7Department of Immunology, Mayo Clinic, Rochester, MN 55905 12 
* These authors contributed equally to this work; **Joint senior authors 13 
 14 
Running Title:  Prime-boost with different immunovirotherapies 15 
 16 
Correspondence should be addressed to R.V. (vile.richard@mayo.edu) / Mayo Clinic, 17 
Guggenheim 18, 200 First Street SW, Rochester, MN 55905 / Phone: 507-284-3178 / FAX: 18 
507-266-2122 19 
 20 
This work was supported by NIH Grants CA175386-01A1 and CA108961-10P3; by the 21 
University of Minnesota/Mayo Foundation Partnership Grant; by Oncolytics Biotech 22 
(Calgary); The European Research Council Advanced Grant (ONCOVIRAX); Vyriad 23 
Pharmaceuticals; and the Mayo Foundation. RV is in receipt of research funding from 24 
Oncolytics. 25 
 26 
There is no conflict of interest.27 
2 
 
ABSTRACT 28 
The anti-tumor effects associated with oncolytic virus therapy are mediated significantly 29 
through immune-mediated mechanisms which depends both on the type of virus and the 30 
route of delivery.  Here, we show that intra-tumoral (i.t.) oncolysis by Reovirus induced the 31 
priming of a CD8+, Th1-type anti-tumor response.  In contrast, systemically delivered VSV 32 
expressing a cDNA library of melanoma antigens (VSV-ASMEL) promoted a potent anti-33 
tumor CD4+ Th17 response.  Therefore, we hypothesised that combining the Reovirus-34 
induced CD8+ T cell response, with the VSV-ASMEL CD4+ Th17 helper response, would 35 
produce enhanced anti-tumor activity. Consistent with this, priming with i.t. Reovirus, 36 
followed by an intra-venous VSV-ASMEL Th17 boost, significantly improved survival of mice 37 
bearing established subcutaneous (s.c.) B16 melanoma tumors.  We also show that 38 
combination of either therapy alone with anti-PD-1 immune checkpoint blockade augmented 39 
both the Th1 response induced by systemically delivered Reovirus in combination with GM-40 
CSF, and also the Th17 response induced by VSV-ASMEL.  Significantly, anti-PD-1 also 41 
uncovered an anti-tumor Th1 response following VSV-ASMEL treatment that was not seen 42 
in the absence of checkpoint blockade.  Finally, the combination of all three treatments 43 
(priming with systemically delivered Reovirus, followed by double boosting with systemic 44 
VSV-ASMEL and anti-PD-1) significantly enhanced survival, with long-term cures, compared 45 
to any individual, or double, combination therapies, associated with strong Th1 and Th17 46 
responses to tumor antigens. Our data show that it is possible to generate fully systemic, 47 
highly effective anti-tumor immunovirotherapy by combining oncolytic viruses, along with 48 
immune checkpoint blockade, to induce complimentary mechanisms of anti-tumor immune 49 
responses.   50 
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INTRODUCTION 51 
Oncolytic viruses (OV) are naturally occurring or genetically modified viruses that target 52 
tumor cells while largely sparing normal cells, dependent on a number of different 53 
mechanisms1-3.  In this respect, it is now clear that the anti-tumor activity of these agents is, 54 
at least in part, dependent on immune responses raised to both the virus and tumor 55 
associated antigens released during the process of immunogenic tumor cell killing4-6.  This 56 
concept is underscored by the recent FDA approval of talimogene laherparepvec (T-Vec, an 57 
HSV encoding GM-CSF), confirming the potential of OV as immunovirotherapeutic agents 58 
for cancer treatment.    59 
The exact immune mechanisms through which OV induce anti-tumor responses depend 60 
upon multiple factors, including the type of virus used, the route of administration of the virus 61 
and the transgenes encoded.  In this respect, we, and others, have shown that immune 62 
responses mediated by a range of OV encoding either tumor antigens (Ag), cytokines and/or 63 
co-stimulatory molecules, are effective in controlling tumor growth in pre-clinical models7-10, 64 
with several of these agents being tested in clinical trials11-13.  For example, Reovirus 65 
replication occurs in tumor cells with defective anti-viral PKR signalling resulting in 66 
oncolysis14 but also generates potent anti-tumor immune responses, both innate and 67 
adaptive, which are highly important for tumor regression15-18.  A number of Phase1/2 clinical 68 
trials of Reovirus serotype 3 Dearing (Oncolytics Biotech) have demonstrated it to be safe19-69 
21.  We have shown that, when delivered intra-tumorally (i.t.), Reovirus generates a Th1 anti-70 
tumor response22, which also correlates with our previous observations that Reovirus 71 
activates CTL16, 17.  However, when delivered systemically in combination with GM-CSF, we 72 
showed that the anti-tumor immune response is also heavily dependent on innate 73 
mechanisms23.   74 
We have also developed an effective systemic immunovirotherapy against established 75 
tumors using Vesicular Stomatitis Virus (VSV) expressing either single, or multiple, tumor 76 
antigens.  In particular, i.v. delivery of VSV expressing a cDNA library derived from either 77 
normal, or tumor, cells primed specific anti-tumor immune responses in models of 78 
4 
 
melanoma, prostate cancer and brain tumors 10, 24, 25.  Interestingly, in all of these models, 79 
the anti-tumor immune responses primed against tumor by expression of multiple tumor 80 
antigens encoded by the virally-expressed cDNA were dependent upon CD4+ Th17 cells10, 81 
24. 82 
Normal immune responses to infection or injury are modulated at checkpoints to prevent 83 
them leading to uncontrolled immune cell proliferation and auto-immune disease. For 84 
example, Programmed cell death-1 (PD-1) is a receptor found on immune cells including T 85 
cells, B cells and monocytes26 binding of which to one of its ligands, PD-L1 or PD-L2, inhibits 86 
immune cell activation.  Expression of PD-L1 is found on many types of tumor27 resulting in 87 
the ability of tumor cells to evade immune responses against them.  Checkpoint inhibitors 88 
are antibodies which target these negative immune regulators or their ligands, including 89 
PD1/PD-L1, and have shown great promise as immune therapy for the treatment of at least 90 
a proportion of patients with melanoma and other cancers28-30.  These data clearly suggest 91 
that these checkpoint inhibitors relieve repression of (weak) T cell responses against self 92 
tumor associated antigens, as well as against pathogens associated with infection and 93 
injury.   Therefore, given that OV can prime anti-tumor T cell responses, several groups have 94 
proposed that the combination of OV therapy and checkpoint inhibition will be of 95 
immunotherapeutic value 22, 25, 31, 32.   96 
In the current study, we hypothesised that a combination of two different forms of oncolytic 97 
viroimmunotherapy, which stimulate alternative CD8+ Th1 and CD4 helper Th17 98 
mechanisms of anti-tumor immunity, could combine co-operatively or synergistically, along 99 
with immune checkpoint blockade, to enhance anti-tumor therapy. We show here a 100 
Th1/Th17 prime-boost treatment with two different viruses, both delivered systemically, was 101 
significantly more effective in controlling tumors than either single immunovirotherapy 102 
treatment alone. Further addition of immune checkpoint blockade with anti-PD-1, generated 103 
long term cures in mice treated with the triple combination therapy under experimental 104 
conditions where double therapies alone did not. 105 
 106 
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RESULTS 107 
Reovirus primes a Th1 response, while VSV-cDNA primes a Th17 response against B16 108 
melanoma. 109 
Pooled cultures of splenocytes and lymph node (S/LN) cells from mice treated intra-110 
tumorally (i.t.) with Reovirus, but not with PBS, secreted IFN-γ in response to B16 tumor cell 111 
lysates (Fig.1A).  They also generated a Th1 recall response to a combination of the three 112 
VSV-expressed self antigens (VSV-NRAS, VSV-CYT-c, VSV-TYRP1), which we have 113 
previously described as rejection antigens for B16 tumors following treatment with a VSV-114 
ASMEL cDNA library24 (Fig.1A, VSV-combo).  However, no IL-17 (< 50 pg/ml, data not 115 
shown) was detected as a result of i.t. Reovirus treatment indicating the absence of a Th17 116 
immune response.   117 
In this s.c. B16 model, we have shown that single agent Reovirus delivered i.t., but not 118 
intravenously (i.v.), was an effective anti-tumor therapy33.  In contrast, established B16 119 
tumors could be treated with a systemically delivered VSV-cDNA library (VSV-ASMEL –  120 
Altered Self Melanoma Eptiope Library)10.  The anti-tumor response was dependent on 121 
CD4+ T cells and associated with a Th17 response against at least three dominant tumor 122 
Ag, NRAS, CYT-c and TYRP124.  Consistent with those data, splenocyte/LN cells from VSV-123 
ASMEL-treated mice secreted IL-17 in response to either B16 lysate or to the VSV-combo 124 
(Fig.1B).  In contrast, no IFN-γ was secreted on re-stimulation with B16 lysate or the VSV-125 
combo (< 50 pg/ml, data not shown), indicating no significant detectable Th1-type response 126 
to this treatment.  Therefore, i.t. Reovirus (Th1), and i.v. VSV-cDNA (Th17), prime different 127 
types of anti-tumor immune response.   128 
 129 
Prime-boost using Reovirus and VSV-ASMEL improves anti-tumor therapy. 130 
Therefore, we hypothesized that a combination of immunovirotherapies working through 131 
different immune mechanisms would enhance overall anti-tumor therapy in the context of a 132 
prime-boost strategy. Using sub-optimal individual treatments either alone, or in 133 
combination, to allow detection of improved efficacy, prime-boost with Reo/PBS, Reo/Reo, 134 
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VSV-ASMEL/VSV-ASMEL, Reo/VSV-GFP and VSV-ASMEL/Reo all resulted in significantly 135 
improved survival compared to PBS/PBS treated controls (Fig.2A, p<0.001 for all).  136 
However, prime-boost with Reo/VSV-ASMEL was a significantly better treatment than any of 137 
the other regimens (Fig.2A, p<0.001 Reo/VSV-ASMEL vs any other treatment).  Increased 138 
survival following Reo/VSV-ASMEL prime-boost was associated with a stronger Th1 recall 139 
response against B16 lysate, or the melanoma tumor antigen TYRP1, compared to that seen 140 
in mice treated with prime-boost Reo/PBS (Fig.2B, p = 0.0140, B16 lysate; p = 0.0023, 141 
TYRP1).  There was a trend towards increased Th17 responses following prime-boost 142 
Reo/VSV-ASMEL treatment compared to PBS/VSV-ASMEL although this did not reach 143 
statistical significance (Fig.2C). IFN-γ or IL-17 recall responses to TC2 F/T lysate, a non-144 
melanoma cell line, were minimal, indicating that the Th1 and Th17 responses were tumor-145 
specific (Figs.2B&C).  146 
 147 
Enhancement of systemic Reovirus therapy by checkpoint blockade is dependent on CD8 148 
cells. 149 
We have previously shown that systemically delivered Reovirus can be effective when used 150 
in combination with other agents such as GM-CSF, cyclophosphamide or VEGF23, 33, 34 or in 151 
the context of ex vivo loaded cell carriage18. In this respect, pre-conditioning with GM-CSF 152 
prior to systemic Reovirus delivery, effectively treated B16 tumors dependent on innate 153 
immune responses23. As before23, a suboptimal regimen of two cycles of GM-CSF/Reovirus 154 
significantly prolonged survival in C57Bl/6 mice bearing 5 day established B16 s.c. tumors 155 
(Fig.3A).  Combination with anti-PD-1 checkpoint blockade resulted in significantly improved 156 
survival (Fig.3A, GM-CSF/Reovirus/anti-PD-1 vs GM-CSF/Reovirus alone, p = 0.0174).  We 157 
observed a low level Th1 response to tumor Ag following GM-CSF/Reovirus treatment, both 158 
by an IFN- recall response to B16 tumor lysate (Fig.3B), and by significantly increased 159 
numbers of IFN- secreting CD8+ T cells (p=0.012) and CD4+ T cells (p=0.009) infiltrating 160 
into GM-CSF/Reovirus-treated tumors compared to PBS-treated tumors (Fig.3C).  However, 161 
this Th1 response was significantly improved by the addition of anti-PD-1 (Fig.3B, GM-162 
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CSF/Reovirus/anti-PD-1 vs GM-CSF/Reovirus, p = 0.0250).  Previously we showed that GM-163 
CSF/Reovirus therapy is largely mediated by innate effectors such as natural killer (NK) cells 164 
and monocytes23. Similarly, despite the increased numbers of CD8+ T cells in treated 165 
tumors, depletion of neither CD8, nor CD4, cells significantly affected survival after treatment 166 
with GM-CSF/Reovirus (Fig.3D).  Interestingly, we observed a trend for increased survival 167 
with depletion of CD4+ T cells (Fig.3D). Although this was not statistically significant, we are 168 
currently testing the hypothesis that depletion of CD4+ T cells leads to removal of a 169 
suppressive population, which enhances the innate-immune mediated clearance of tumors 170 
induced by GM-CSF/Reovirus treatment.  However, consistent with the improved Th1 171 
response seen on addition of anti-PD1 (Fig.3B), depletion of CD8, but not CD4, cells 172 
significantly reduced survival in mice treated with GM-CSF/Reovirus + anti-PD-1 (Fig.3E, p = 173 
0.0135).  No Th17 response was detected following GM-CSF/Reovirus treatment, with, or 174 
without, addition of anti-PD-1 (IL-17 < 20 pg/ml, data not shown).  These data suggest that, 175 
although the effect of GM-CSF/Reovirus is mainly mediated via innate effectors, a 176 
detectable, but low level Th1 response was also generated but did not contribute 177 
significantly to tumor control.  However, in the presence of checkpoint blockade this weak 178 
Th1 response was significantly enhanced, which translated into improved overall survival.  179 
 180 
Checkpoint inhibition improves VSV-ASMEL therapy and uncovers a Th1 anti-tumor 181 
response. 182 
The addition of anti-PD-1 significantly prolonged survival of mice with established s.c. B16 183 
tumors treated with VSV-ASMEL alone (Fig.4A, VSV-ASMEL + anti-PD-1 vs VSV-ASMEL + 184 
control IgG, p = 0.018).  Improved survival following VSV-ASMEL + anti-PD-1 was 185 
associated with a significantly stronger Th17 recall response against B16 lysate compared to 186 
VSV-ASMEL alone (Fig.4B, p = 0.001).  Furthermore, anti-PD-1 treatment uncovered a Th1 187 
response to tumor as evidenced by production of IFN-γ from splenocyte/LN cells in response 188 
to B16 lysate (Fig.4C, p = 0.0014), which was not detectable in the absence of anti-PD-1.   189 
 190 
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Combined Th1/Th17 therapy, together with checkpoint inhibition, cures B16 melanoma. 191 
Finally, we hypothesized that combining an innate-driven/Th1 Reovirus-induced anti-tumor 192 
response, with a Th17 VSV-ASMEL-induced response, both of which were enhanced with 193 
anti-PD-1 blockade, would generate more effective anti-tumor therapy than either alone. As 194 
before, GM-CSF/Reovirus was effective in treating s.c. B16 tumors (Fig.5A, p = 0.0004 vs 195 
PBS), while combination with anti-PD-1 further improved survival (Figs.3A&5A).  As with i.t. 196 
Reovirus + VSV-ASMEL (Fig.2A), prime-boost with systemic GM-CSF/Reovirus followed by 197 
VSV-ASMEL, was superior to GM-CSF/Reovirus alone (Fig.5A).  However, addition of anti-198 
PD-1 to the GM-CSF/Reovirus/VSV-ASMEL prime-boost treatment was the only therapy 199 
able to generate long-term cures under these experimental conditions (Fig.5A, p < 0.01 vs 200 
GM-CSF/Reo, GM-CSF/Reo/anti-PD-1, GM-CSF/VSV-ASMEL).  Splenocyte/LN cultures 201 
from the long-term cured mice produced significantly higher levels of IFN-γ in response to 202 
B16 lysate than mice from any other treatment group which had been euthanised earlier due 203 
to tumor burden,  (Fig.5B, p = 0.00006).  This Th1 recall response included a specific 204 
component against the melanoma Ag TYRP1 (Fig.5B, p = 0.0216 vs control group).  In 205 
addition, mice treated with GM-CSF/Reovirus/VSV-ASMEL + anti-PD-1had a significantly 206 
improved Th17 recall response compared to those treated with the prime-boost regimen 207 
without checkpoint blockade (Fig.5C, p = 0.0156).  These data show that two separate 208 
oncolytic immunovirotherapies, working through different immune effector mechanisms, and 209 
combined with checkpoint blockade, can be effectively combined to eradicate established 210 
disease. 211 
 212 
DISCUSSION 213 
It is now clear that the efficacy of many oncolytic virus regimens depends upon an immune 214 
component.  Thus, Reovirus is effective against B16OVA tumors which are not susceptible 215 
to direct oncolysis17, and systemic VSV did not generate significant anti-tumor therapy in 216 
nude mice35.  However, the immunological mechanisms of such effects will vary between 217 
virus types, routes of administration and transgenes encoded by the viruses.  In this respect, 218 
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we show here that, whereas i.t. injection of oncolytic Reovirus primed a Th1-type response 219 
to B16 s.c. tumors, systemic administration of the VSV-ASMEL cDNA library primed a Th17 220 
response to tumor-specific Ag.  Therefore, we hypothesized that combining complementary 221 
immunological effector pathways, induced by different oncolytic viruses, would generate 222 
improved immune-mediated anti-tumor therapy.   223 
Repeated treatment with the same type of immunovirotherapy (Reo/Reo (Th1) or VSV-224 
ASMEL/VSV-ASMEL (Th17)) resulted in prolonged survival compared to PBS-treated 225 
controls (Fig.2A).  However, combination Reovirus/VSV-ASMEL (Th1/Th17) prime-boost 226 
treatment significantly improved survival compared to repeated single therapies (Fig.2A), 227 
associated with enhanced Th1, and, to a lesser extent, Th17 anti-tumor Ag responses, 228 
(Figs.2B&C).  Interestingly, reversing the order of the prime-boost from Th1/Th17 to 229 
Th17/Th1 still significantly improved survival compared to controls.  However, this 230 
improvement was only comparable to single repeated immunovirotherapies and was 231 
significantly less effective than the Th1/Th17 prime-boost (Fig.2A).  These data show that 232 
two different oncolytic viruses, each priming a different type of immune response, can be 233 
combined to produce significantly better therapy than either virus alone.  Furthermore, the 234 
order in which the responses were induced was important (Th1 followed by Th17).     235 
As part of our long term goal to develop delivery regimens for oncolytic immunovirotherapy 236 
which do not necessitate direct i.t. injection, we developed an effective systemic Reovirus 237 
therapy by pre-conditioning tumor-bearing mice with GM-CSF prior to i.v. Reovirus injection, 238 
which is mediated by NK cells and CD11b+ monocytes23.  We have also shown that 239 
Reovirus-mediated NK cell activation following i.t. Reovirus injection was augmented by anti-240 
PD-1 leading to improved tumor therapy22.   Therefore, we investigated whether anti-PD-1 241 
could improve our systemic Reovirus treatment. Fig.3A shows that addition of anti-PD-1 242 
treatment significantly enhanced survival of mice compared to GM-CSF/Reovirus alone.  243 
Significantly, this improvement in therapy was associated with an enhanced Th1 response to 244 
B16 tumor Ag, which was only minimally detected in the absence of anti-PD-1 (Fig.3B).  The 245 
improved therapy was also dependent upon CD8+ T cells (Figs.3B&E), consistent with the 246 
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mechanism of checkpoint blockade as acting predominantly via release of inhibition on T 247 
cells36-38.  These data show that checkpoint blockade mechanistically enhanced systemic 248 
GM-CSF/Reovirus therapy by significantly augmenting an otherwise very weak CD8+ T cell 249 
dependent component which was associated with significantly better anti-tumor therapy.   250 
Similarly, although therapy associated with systemic delivery of VSV-ASMEL was dependent 251 
upon CD4+ T cells and a Th17 response (Fig.4B), with no detectable Th1 response 252 
(Fig.4C), addition of anti-PD-1 uncovered a Th1 response to tumor Ag that was not 253 
detectable in the absence of checkpoint blockade (Fig.4C).  As for the addition of anti-PD-1 254 
to the GM-CSF/Reovirus regimen, uncovering of this anti-tumor Th1 response was 255 
associated with extended survival, and increased tumor cures, in vivo (Fig.4A).  Anti-PD-1 256 
also moderately enhanced the anti-tumor Th17 response against B16 tumor Ag (Fig.4B).  257 
We are currently investigating the possibility that anti-PD-1 therapy acts so effectively to 258 
augment these otherwise undetectable Th1 T cell responses (for both GM-CSF/Reovirus 259 
and VSV-ASMEL treatments), through direct activity on suppressive cells such as MDSC or 260 
Treg induced in response to virotherapy.   261 
Since the combination of GM-CSF/Reovirus and VSV-ASMEL therapy enhanced therapy 262 
compared to either alone (Fig.2), and since both mono-immunovirotherapies were 263 
significantly enhanced by anti-PD-1 checkpoint inhibition (Figs.3&4), we tested the 264 
combination of all three therapies.  As seen in Fig.5, the triple therapy (GM-CSF/Reovirus 265 
(innate immune mediated, C8+T Th1lo) + VSV-ASMEL boost (CD4+ Th17, Th1lo) + anti-PD-1 266 
(Th1 and Th17 enhancement) was significantly more effective than any of the double 267 
combinations, resulted in tumor regression with 100% of the mice cured long term at day 70, 268 
and was associated with very strong Th1 and Th17 responses to tumor antigens, including 269 
TYRP-1 (Fig 5).  The data of Figs 4B&C and 5B&C, show that long term survival and tumor 270 
cure correlated with the development of both anti-tumor Th1 and Th17 recall responses.  In 271 
contrast, development of either alone, or neither response, was associated with significantly 272 
shorter long term survival.  These assays were performed on splenocytes from mice at the 273 
time of sacrifice due to tumor burden or at day 100 (Fig.4) or 70 (Fig.5), following tumor 274 
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seeding for the long term survivors.  We did not perform similar assays on mice at a defined 275 
time point following treatment because we believe that the multiple components of the innate 276 
and adaptive immune responses that are operative with the full combination therapy would 277 
not have developed fully by the early time points at which control treated mice started to die 278 
due to tumor burden.   279 
Our data are consistent with a model in which primary treatment with GM-CSF/Reovirus 280 
leads to initial tumor killing through virus delivery and innate immune activation23.  This 281 
therapy induced detectable, but very low level, Th1 responses against tumor antigens 282 
(Fig.3B).  We hypothesise that, critically, initial tumor killing releases a very broad range of 283 
tumor Ag, against which only very weak anti-self T cell responses can be primed.   284 
Subsequent delivery of VSV-ASMEL provides a similarly broad range of tumor Ag in the 285 
form of the cDNA library.  These stimulate CD4+ Th17 responses which can, therefore, 286 
provide additional help to the T cell responses stimulated by the primary GM-CSF/Reovirus 287 
treatment (Fig.2B&C).  Finally, late boosting with anti-PD-1 further augments both the 288 
already enhanced Th1 and Th17 responses against this broad range of tumor antigens 289 
leading to the potent and sustained therapy observed in Fig.5.     290 
Several other groups have also successfully used combinations of oncolytic viruses for 291 
tumor therapy consistent with a heterologous prime-boost strategy to generate efficient anti-292 
tumor Ag-specific therapy.  For example, rhabdoviruses, such as VSV or Maraba virus, 293 
expressing a defined melanoma associated antigen, provided an effective immunological 294 
boost against the antigen in mice previously vaccinated with an adenoviral vector to prime 295 
the response 39, 40.  Tysome et al. showed that sequential treatment with oncolytic 296 
adenovirus and vaccinia viruses cured about 60% of tumor bearing Syrian Hamsters.  297 
Efficacy was dependent upon the sequence of the virus treatments, and, significantly, upon 298 
CD3+ T cells, indicating that the combination of viruses was acting through an 299 
immunological prime-boost-like mechanism 41.   The combination of adenovirus and vaccinia 300 
virus was also successful in slowing anti-viral, and innate cellular, immune responses 301 
leading to better anti-tumor therapy 42.  Similarly, a combination of Semliki Forest Virus and 302 
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Vaccinia virus was effective at boosting anti-tumor immune responses in a murine ovarian 303 
cancer model and generated improved therapy through both oncolysis and enhanced anti-304 
tumor immunity 43.  Our approach here moves beyond the use of different vectors encoding 305 
specific antigens and uses the release of multiple antigens through oncolysis as the basis of 306 
the priming step, which is then boosted by the use of the cDNA library.  We believe that 307 
raising T cell responses against multiple tumor antigens simultaneously reduces the ability of 308 
tumor cells to escape immune pressure by developing antigen loss variants. Our approach 309 
here is also novel in that it specifically exploits the complementary immunological 310 
mechanisms by which two oncolytic viruses (Reovirus and VSV) stimulate anti-tumor 311 
immunity through different immune effectors. 312 
In summary, we show here that it is possible to combine oncolytic viruses, which induce 313 
complimentary mechanisms of anti-tumor immune responses, along with immune checkpoint 314 
blockade, to generate fully systemic, highly effective anti-tumor immunovirotherapy.    315 
 316 
MATERIALS AND METHODS 317 
Cell lines.  Murine B16 melanoma and TRAMP-C2 (TC2) prostate tumor cells were grown in 318 
DMEM (Life Technologies) supplemented with 10% (v/v) FCS (Life Technologies) and L-319 
glutamine (Life Technologies).  Cell lines were monitored routinely and found to be free of 320 
Mycoplasma infection.   321 
Viruses.  Wild type Reovirus type 3 (Dearing strain, REOLYSIN) was obtained from 322 
Oncolytics Biotech (Calgary, Canada).  Stock titers were measured by plaque assays on 323 
L929 cells.  The ASMEL VSV-cDNA library was generated as previously reported10, 24, 44.  324 
Individual viral clones were isolated by limiting dilution as previously described24, 44, 325 
expanded in BHK cells and purified by sucrose gradient centrifugation.  VSV-GFP was 326 
manufactured as described45. 327 
In vivo experiments.  6-8 week old female C57Bl/6 mice were purchased from Jackson 328 
Laboratories (Bar Harbor, Maine).  All in vivo studies were approved by the Mayo IACUC.  329 
Mice were challenged subcutaneously with 2x105 B16 melanoma cells in 100 μL PBS 330 
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(HyClone).  Tumors were measured 3 times per week, and mice were euthanized when 331 
tumors reached 1.0 cm diameter.  Reovirus was administered i.v. at 5x107 or i.t. at 1x108 332 
TCID50 per injection; VSV-GFP and VSV-ASMEL were administered i.v. at 1x10
7 pfu per 333 
injection.  GM-CSF was administered i.p. at 300 ng/injection, as described previously23, 1 334 
cycle of GM-CSF/Reo = GM-CSF i.p. on 3 consecutive days followed by Reovirus 335 
(5x107TCID50) i.v. on the following 2 days.  Anti-PD-1 (BioXcell, West Lebanon, NH) or 336 
control IgG (BioXcell) was given i.v. at either 225 or 250 μg per injection as detailed in the 337 
figure legends.  Anti-CD4 (GK1.5, BioXcell) or anti-CD8 antibodies (Lyt2.43, BioXcell) for cell 338 
depletions were administered i.p. at 100 µl per injection. 339 
Definitions and Dosing Regimens Used in these Studies:   340 
VSV-ASMEL:  A VSV-cDNA library expressing cDNA from human melanoma cell lines 341 
which, therefore encode altered self epitopes in the mouse (VSV-ASMEL –  Altered Self 342 
Melanoma Epitope Library).  Previously, we have shown that 9 i.v. injections of the VSV-343 
cDNA library (VSV-ASMEL) can cure ~80% of mice with 5 day established, subcutaneous 344 
B16 tumors 24.   345 
GM-CSF/Reovirus:  A treatment schedule in which a single cycle consists of GM-CSF 346 
administered i.p. on days 1&2 followed by intravenous Reovirus on days 3,4&5.  Previously, 347 
we have shown that three of these cycles of GM-CSF/Reovirus, over a period of three 348 
weeks, cured 60-80% of mice with 5d-established s.c. tumors 23.    349 
In the studies reported here, we required models in which either VSV-ASMEL or GM-350 
CSF/Reovirus alone would have diminished therapy, in order to investigate whether 351 
combination with each other, and/or checkpoint inhibition would enhance therapy.  To 352 
achieve this, we reduced the starting tumor burden and/or the number of injections of VSV-353 
ASMEL or GM-CSF/Reovrus depending upon the experimental situations as follows: 354 
Figure 2:  Tumor burden was increased at the time of treatment from 5 day- to 10 day-355 
established tumor and the number of systemic injections of VSV-ASMEL was reduced from 356 
9 (optimally therapeutic) to 3.  Under these conditions, i.v. VSV-ASMEL was significantly 357 
better than PBS but led to no cures. 358 
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Figure 3:  Tumor burden was kept at 5 day established s.c. B16 but therapy with GM-359 
CSF/Reovirus was reduced relative to the optimal protocol by administering only two cycles 360 
of GM-CSF/Reovirus instead of 3.  Under these circumstances only ~15% of mice were 361 
cured but all mice had significant prolongation of survival before tumors reached 1.0 cm 362 
diameter.  This condition allowed a significant improvement in therapy with GM-363 
CSF/Reovirus to be shown with the addition of anti-PD-1 therapy. 364 
Figure 4:  Tumor burden was kept at 5 day established s.c. B16.  However, the number of 365 
systemic injections of VSV-ASMEL was reduced from 9 (optimally therapeutic) to 6.  Under 366 
these conditions, i.v. VSV-ASMEL was significantly better than i.v. VSV-GFP but led to 367 
significantly fewer cures (~25%) than with 9 i.v. injections of VSV-ASMEL.  This condition 368 
allowed a significant improvement in therapy with VSV-ASMEL to be shown with the addition 369 
of anti-PD-1 therapy. 370 
Figure 5:  Tumor burden was increased at the time of treatment from 5 day- to 10 day-371 
established tumor. Priming therapy with GM-CSF/Reovirus was reduced relative to the 372 
optimal protocol by administering only two cycles of GM-CSF/Reovirus instead of the optimal 373 
3.  The increased tumor burden made the therapy of GM-CSF/Reovirus+anti-PD-1 less 374 
effective here (all mice with tumor by d70) than the same therapy in Figure 3 (~80% cured 375 
of tumor by day 80).  The number of systemic injections of VSV-ASMEL was reduced from 9 376 
(optimally therapeutic) to just 3, which, along with the larger tumor burden, made VSV-377 
ASMEL therapy completely ineffective, which could not be rescued by the addition of anti-378 
PD-1 (VSV-ASMEL/anti-PD-1).  This lack of therapy was in contrast to Figure 4 where a 379 
smaller starting tumor burden, and more i.v. injections of VSV-ASMEL, generated better 380 
single agent therapy which was enhanced by anti-PD-1.  Under these conditions, significant 381 
improvement in therapy with either VSV-ASMEL+anti-PD-1 or GM-CSF/Reovirus+anti-PD-1 382 
could be shown with the triple prime-boost combination of GM-CSF/Reovirus+VSV-383 
ASMEL+anti-PD-1.           384 
 385 
15 
 
In vitro splenic re-stimulation of splenocytes/lymph nodes and enzyme-linked 386 
immunosorbent assay for IFN-γ/TNF-α.  Spleen and lymph nodes (S/LN) were 387 
immediately excised from euthanized mice and dissociated in vitro to achieve single-cell 388 
suspensions.  S/LN cells were pooled for each individual mouse.  Red blood cells were lysed 389 
with ACK lysis buffer for 2 min.  Cells were re-suspended in Iscove’s modified Dulbecco’s 390 
medium (Gibco, Grand Island, NY) + 5% FBS + 1% Pen-Strep + 40 μM 2-ME.  Supernatants 391 
were harvested from 1 x 106 S/LN stimulated with one of the following: VSV-combination 392 
(VSV-NRAS, VSV-CYT-c, VSV-TYRP1) at MOI=1 per stimulation; 1 µg/ml synthetic H2-b-393 
restricted peptides murine TRP-2180–188 SVYDFFVWL (H2K
b), murine TRP-1222–229 394 
TAYRYHLL (H2Kb), human gp10025–33 (Hgp100) KVPRNQDWL (H2D
b), murine gp10025-33 395 
(Mgp100) EGSRNQDWL (H2Db) or with freeze-thaw lysates (equivalent to 1 x 106 tumor 396 
cells), from B16 (relevant) or TC2 (irrelevant) tumor cells every 24 h.  Cell-free supernatants 397 
were collected at 48 or 72 h and tested by enzyme-linked immunosorbent assay for murine 398 
IFN-γ or murine IL-17 (BD Biosciences, San Jose, CA). The peptides were synthesized at 399 
Mayo Foundation Core Facility (Rochester, MN). 400 
Statistics.  Survival data from the animal studies were analyzed by the log-rank test using 401 
GraphPad Prism 6 Software. A Student’s t-test analysis was applied for in vitro data. 402 
Statistical significance was determined at the level of P < 0.05.  403 
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FIGURE LEGENDS 541 
Figure 1:  Reovirus primes a Th1 response, while VSV-cDNA primes a Th17 response 542 
against B16 melanoma.  A&B. C57Bl/6 mice (4 per group) bearing 10 day established B16 543 
tumors, received 6 i.t. injections of either PBS or Reovirus on days 10,12,14,17,19,21 (A), 544 
and C57Bl/6 mice (4 per group) bearing 5 day established B16 tumors, received 6 i.v. 545 
injections of either VSV-GFP or VSV-ASMEL on days 5,7,9,12,14,16. (B). At day 25, mice 546 
were euthanised, spleens and LN dissociated into single cell suspensions and re-stimulated 547 
with either: B16 F/T lysate; VSV-NRAS + VSV-CYT-c + VSV-TYRP1 (VSV-combo, total 548 
MOI=1 per re-stimulation) or peptide as indicated (1 µg/ml per re-stimulation), every 24 h.  549 
Supernatants were harvested after 48 h and tested for IFN-γ and IL-17 by ELISA. Graphs 550 
show values +SD (triplicate wells) for individual mice.  *p<0.05, **p<0.01 two-tailed t-test. 551 
 552 
Figure 2:  Prime-boost using Reovirus and VSV-ASMEL improves anti-tumor therapy.  553 
A. C57Bl/6 mice (7 per group) bearing 10 day established B16 tumors, received 3 i.t. 554 
injections of either PBS, Reovirus or VSV-ASMEL on days 10,12,14 followed by 3 i.v. 555 
injections of either PBS/Reovirus/VSV-ASMEL on days 17,19,21 as indicated.  Tumor 556 
measurements were taken 3x per week and mice euthanised when tumors reached 1.0 cm 557 
diameter.  Graph shown is representative of n=2 individual experiments, ***p<0.001 Log-558 
Rank test Reo/VSV-ASMEL compared to all other groups.   B&C.  At time of sacrifice due to 559 
tumor burden, S/LN were harvested from 3 mice per group.  Single cell suspension cultures 560 
of S/LN were re-stimulated with either, B16 (relevant) or TC2 (irrelevant) F/T lysate, or 561 
TYRP1 peptide, every 24h.  Supernatants were harvested after 72h and tested for IFN-γ and 562 
IL-17 by ELISA. Bars on graphs show values for individual mice.  *p<0.05, **p<0.01 two-563 
tailed t-test. 564 
 565 
Figure 3: Enhancement of systemic Reovirus therapy by checkpoint blockade is 566 
dependent on CD8 cells.  A&B. C57Bl/6 mice (7 per group) bearing 5 day established B16 567 
tumors, were treated ± 2 cycles of GM-CSF/Reovirus beginning on days 5 and 12, then 3 568 
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injections of anti-PD-1 (250 µg) or control IgG on days 19,21,23.  A. Tumors were measured 569 
3x per week and mice euthanised when tumors reached 1.0 cm diameter.  *p<0.05 Log-570 
Rank test.  B. S/LN were harvested at time of sacrifice (as indicated).  Single cell suspension 571 
cultures of S/LN were re-stimulated with B16 F/T lysate every 24 h.  Supernatants were 572 
harvested after 72 h and tested for IFN-γ by ELISA. Bars on graphs show values +SD 573 
(triplicate wells) for individual mice.  *p<0.05 two-tailed t-test.  C.  Mice with 6 day 574 
established subcutaneous B16 tumors were treated with two rounds of PBS/PBS, PBS/Reo, 575 
GM-CSF/PBS or GM-CSF/Reovirus (days 6-10 and 13-17).  On day 22 tumors were excised 576 
and analysed by intracellular staining for CD3+ CD8+ IFN-+, and CD3+ CD4+ IFN-+, T 577 
cells.  The mean percentage of CD3+ CD4+ or CD3+ CD8+ cells, which were also IFN- 578 
positive, in tumors from each group is shown.  Standard deviations represent values from 4 579 
mice per group (except GM-CSF/PBS where n=3).  *p<0.05, **p<0.01 two-tailed t-test. D&E. 580 
C57Bl/6 mice (5 per group) bearing 5 day established B16 tumors, received 3 cycles of GM-581 
CSF/Reovirus with co-injection of anti-CD4 or anti-CD8 depleting antibodies along with the 582 
GM-CSF, begining on days 5,12,19.  Anti-PD-1 (250 µg) or control IgG was administered on 583 
days 19,21,23.  Tumors were measured 3x per week and mice euthanised when tumors 584 
reached 1.0 cm diameter.  D. Depletion of CD4 or CD8 cells on GM-CSF/Reovirus therapy; 585 
E. Depletion of CD4 or CD8 cells on GM-CSF/Reo/anti-PD-1 therapy.  *p<0.05 Log-Rank 586 
test. D&E are results from the same experiment. 587 
 588 
Figure 4: Checkpoint inhibition improves VSV-ASMEL therapy and uncovers a Th1 589 
anti-tumor response.  C57Bl/6 mice (7-8 per group) bearing 5 day established B16 tumors, 590 
received 6 injections of either VSV-GFP or VSV-ASMEL on days 5,7,9,12,14,16, followed by 591 
6 injections of anti-PD-1 (250 µg) or control Ig on days 19,21,23,26,28,30.  A. Tumor 592 
measurements were taken 3x per week and mice euthanised when tumors reached 1.0 cm 593 
diameter.  Graph shown is representative of n=3 individual experiments, *p<0.05 Log-Rank 594 
test.  B&C. S/LN were harvested from 4 mice/group at time of sacrifice.  Single cell 595 
suspension cultures of S/LN were re-stimulated with B16 F/T lysate every 24 h.  596 
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Supernatants were harvested after 72 h and tested for IL-17 (B) and IFN-γ (C) by ELISA.  597 
Bars on graphs show values +SD (triplicate wells) for individual mice.  **p<0.01, ***p<0.001 598 
two-tailed t-test. 599 
 600 
Figure 5: Combined Th1/Th17 therapy, together with checkpoint inhibition, is effective 601 
in curing B16 melanoma.  C57Bl/6 mice (7 per group) bearing 10 day established B16 602 
tumors, received 2 ‘prime’ cycles of either PBS or GM-CSF/Reovirus starting at days 10 and 603 
17, then 3 ‘boost’ injections of PBS or VSV-ASMEL on days 24,26,28.  Anti-PD-1 (225 µg) or 604 
control IgG was given on days 24,26,28,31,33,35.  A. Tumor measurements were taken 3x 605 
per week and mice euthanised when tumors reached 1.0 cm diameter.  Graph shown is 606 
representative of n=2 individual experiments, **p<0.01 Log-Rank test.  B&C. S/LN were 607 
harvested from 3 mice/group at time of sacrifice (as indicated in C).  Single cell suspension 608 
cultures of S/LN were re-stimulated with B16 F/T lysate or peptide as indicated, every 24 h.  609 
Supernatants were harvested after 72 h and tested for IFN-γ (B) and IL-17 (C) by ELISA. 610 
Bars on graphs show values +SD (triplicate wells) for individual mice.  *p<0.05, ***p<0.001 611 
two-tailed t-test. 612 
